STOCKHOLDERS' EQUITY (Tables)

9 Months Ended

Sep. 30, 2023

STOCKHOLDERS' EQUITY [Abstract]

Schedule of Assumptions

The following assumptions were used to determine the fair value of options granted during the nine months ended September 30, 2023 and 2022:

	Nine Months Ended September 30,
	2023	2022
Expected term	5.5 - 6.3 years	5.5 - 6.3 years
Volatility	68%	68%
Dividend yield	0.0	0.0
Risk-free interest rate	4.20-4.24%	1.72-1.73%

Schedule of Option Activity

A summary of the Company’s option activity under the Company’s equity incentive plans and related information is as follows:

	Shares			Weighted Average Exercise Price
Options outstanding, vested and expected to vest at December 31, 2022		8,256,211		$	3.37
Forfeited		(96,392	)	$	2.71
Expired		(236,878	)	$	6.53
Granted		1,727,510		$	3.35
Exercised		(3,809,210	)	$	3.15
Options outstanding, vested and expected to vest at September 30, 2023		5,841,241		$	3.39
Options exercisable		3,163,516		$	3.91

Schedule of Unvested RSU Activity

A summary of the Company’s unvested RSU activity and related information is as follows:

	Shares			Weighted Average Grant Date Fair Value
Balance at December 31, 2022		2,866,987		$	1.59
Granted		3,345,760		$	3.42
Vested		(1,032,698	)	$	1.69
Forfeited		(302,567	)	$	2.64
Balance at September 30, 2023		4,877,482		$	2.94

Schedule of Stock-Based Compensation Expense

Total stock-based compensation expense for all awards granted under the Company’s equity incentive plans for the three and nine months ended September 30, 2023 and 2022 is as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
Research and development	$	12,328	$	4,952	$	27,131	$	14,521
Plasma center operating expenses		41,346		21,588		104,108		62,255
Selling, general and administrative		1,450,454		1,187,043		3,838,651		3,772,860
Cost of product revenue		190,513		99,911		471,955		296,293
Total stock-based compensation expense	$	1,694,641	$	1,313,494	$	4,441,845	$	4,145,929